Welcome on board!
Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.
Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.
Date
Number of shares composing the share capital
Theoretical number of voting rights
December 21, 2021
71,093,253 (1)
78,395,100
(1) This table will be subject to a monthly update of the number of shares issued from the convertible bond program announced on June 7, 2021, with Global Tech Opportunities 13, and detailed in follow-up tables available on the website https://equityline.vox-aequitas.com/pharnext
Stock Market
Euronext Growth Paris
Mnemo
ALPHA
Bloomberg
ALPHA/FR – Reuters: ALPHA.PA
ISIN Code
FR0011191287
Closing date
31 December
First day of trading
18 July 2016
Number of shares
See table above
Indices
EnterNext© PEA-PME 150,
Euronext Growth All-Share, Next Biotech, PEA
Liquidity contract
Kepler Cheuvreux
Eligible to PEA-PME (French fiscal advantage)
Share price
The analysts listed on the right follow PHARNEXT. Any opinions, estimates or forecasts made by these analysts regarding PHARNEXT are individual and do not represent opinions, forecasts or predictions of PHARNEXT's management. PHARNEXT does not by its reference or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations. Requests for copies of analyst reports should be directly addressed to the above-mentioned analyst and institution.
Kepler Cheuvreux : Damien Choplain - email
Gilbert Dupont : Guillaume Cuvillier - email
Edison Group : Jyoti Prakash - email
Initiation of coverage report*
R&D Day 2020 Event report*
Report on PREMIER trial initiation*
Report on the Open-Label Phase III Extension Study of PXT3003*
R&D Day 2021 Event report*
* These hyperlinks to a third party website are provided for information only and do not constitute an endorsement of any content provided therein.
Experienced Pharmaceutical Industry Executive Dr. Elisabeth Svanberg Appointed as Chairman of Pharnext Board of Directors
Pharnext and Global Tech Opportunities 13 Agree to Stop Convertible Bond Program from End of May 2022
Tirage d’une sixième tranche de 300 obligations convertibles en actions (only in French)
Pharnext appoints Dr. Burkhard Blank as new Chief Medical Officer and Head of Research & Development
Tirage d’une cinquième tranche de 300 obligations convertibles en actions & Nombre total d'actions en circulation et droits de vote (only in French)
Corporate presentation
Pharnext Corporate Presentation
Presentation of the R&D Day 2021
Video recording of the R&D Day 2021
Presentation of the PLEO-CMT-FU extension study update
Recording of the webcast presentation of the PLEO-CMT-FU extension study update
General meeting
General meeting
General meeting
General meeting
General meeting
Letter to shareholders
Letter to Shareholders
Letter to Shareholders
Letter to Shareholders n°4
Letter to Shareholders n°3
Letter to Shareholders n°2
Letter to Shareholders n°1
Regulated Information
Financial report first-half 2021
Auditors’ report on Financial year 2020
Auditors’ report on IFRS Financial statement 2020
Management report 2020 from the board of directors for the 2020 financial year (French only)
2020 Annual Financial results IFRS
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison
Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison